Tvardi director granted 6,000 stock options

Tvardi Therapeutics, Inc. director Michael S. Wyzga received a grant of stock options covering 6,000 shares of common stock.

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. director Michael S. Wyzga received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.7800 per share and expire on June 8, 2036. Following this grant, he holds 6,000 derivative securities directly.

According to the terms, 100% of the shares underlying the option vest on the earlier of June 9, 2027 or the date of Tvardi’s next annual meeting of stockholders, provided he continues serving through the vesting date. This is a compensation-related award rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider WYZGA MICHAEL S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	6,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 6,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Option grant size: 6,000 options Exercise price: $2.7800 per share Underlying shares: 6,000 shares +3 more

6 metrics

Option grant size 6,000 options Stock Option (right to buy) granted to director

Exercise price $2.7800 per share Strike price for underlying common stock

Underlying shares 6,000 shares Common stock underlying the option

Post-grant derivative holdings 6,000 options Total derivative securities following transaction

Option expiration June 8, 2036 Expiration date of the stock option

Vesting date trigger June 9, 2027 or next annual meeting 100% vesting upon earlier of these dates with continuous service

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tvardi Therapeutics (TVRD) disclose for Michael S. Wyzga?

Tvardi Therapeutics reported that director Michael S. Wyzga received a grant of stock options for 6,000 shares of common stock. This is a compensation-related award, not an open-market purchase, and was reported on a Form 4 insider filing.

How many Tvardi Therapeutics (TVRD) options were granted to Michael S. Wyzga and at what price?

Michael S. Wyzga was granted stock options covering 6,000 shares of Tvardi Therapeutics common stock. The options have an exercise price of $2.7800 per share, meaning he can buy shares at that price once the options vest.

When do Michael S. Wyzga’s Tvardi Therapeutics (TVRD) stock options vest?

All 6,000 Tvardi Therapeutics stock options granted to Michael S. Wyzga vest 100% on the earlier of June 9, 2027 or the date of the company’s next annual meeting of stockholders, assuming he remains in continuous service until that vesting date.

What is the expiration date of Michael S. Wyzga’s Tvardi Therapeutics (TVRD) stock options?

The stock options granted to Michael S. Wyzga by Tvardi Therapeutics expire on June 8, 2036. After that date, any unexercised options become worthless, so exercises must occur before this expiration to acquire Tvardi common shares at the set price.

Is Michael S. Wyzga’s Tvardi Therapeutics (TVRD) option grant a market purchase or compensation?

The 6,000-share Tvardi Therapeutics stock option reported for Michael S. Wyzga is a compensation-related grant. The Form 4 labels it as a “Grant, award, or other acquisition,” rather than an open-market buy, with an exercise price of $2.7800 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WYZGA MICHAEL S

(Last) (First) (Middle)

C/O TVARDI THERAPEUTICS, INC.

3 SUGAR CREEK CTR BLVD, STE 525

(Street)

SUGAR LAND TEXAS 77478

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tvardi Therapeutics, Inc. [ TVRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.78	06/09/2026		A		6,000		(1)	06/08/2036	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Dan Conn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)